Atezolizumab: 14 agencies, 2017–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
On the same population the two systems disagree outright: NICE (England) recorded recommended in TA525, while SMC (Scotland) recorded not recommended for “As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma: − after prior platinum-containing chemotherapy, or − who are …”.
HAS (France) has been harder on atezolizumab than on its own caseload: it refused 8 of 13 decisive submissions here (62%), against a base rate of 11% across everything it has assessed.
Assessment has run over 9 years, from 2017 at PBAC (Australia) to 29 Jul 2026 at DMC (Denmark).
SMC (Scotland) changed its position: not recommended on 12 Mar 2018, recommended by 8 Aug 2022, after a resubmission.
No assessment is on file from TLV (Sweden), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for atezolizumab, 2 submissions were never made and 2 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 40 of 120 records date from 2023 or later.
The programme is broad: 32 distinct indication wordings are recorded for atezolizumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
11 of these 120 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess atezolizumab, in 2017; HIRA (South Korea) did not open a file until 7 May 2026 — an unusually long tail of 8.8 years between the earliest and latest system to look at it.
The record arrives in waves: 10 separate years each carry two or more decisions, spread across 10 years in total.
12 of the 14 agencies here assessed atezolizumab more than once, NYE METODER (Norway) most often at 15 entries — repeat review is the norm for this molecule rather than the exception.
atezolizumab has been through 14 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for atezolizumab reads 58 recommended, 24 not recommended, 11 restricted and 8 deferred to NICE, with 19 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2026 | Advanced (unresectable) Barcelona Clinic Liver CancerStage B or Stage C hepatocellular carcinomaExtensive-stage small cell lung cancerResected early stage (Stage II to II… | Not applicable | source |
| HAS (France) | 24 Jun 2026 | Re-assessment following post-listing study results | SMR insufficient · ASMR III | source |
| DMC (Denmark) | 1 Jun 2026 | 1. linjebehandling af ikke-småcellet lungekræft med PD-L1 > 50 % | Anbefalet | source |
| HIRA (South Korea) | 7 May 2026 | 초기 병기 비소세포폐암 PD-L1 발현 비율이 종양세포 (TC) 의 50% 이상인 병기 II-IIIA 비소세포폐암 환자에 대해 절제 및 백금 기반 화학요법 후에 수술 후 보조요법 (adjuvant) | extension of coverage appropriate (risk-share extension) | source |
| PHARMAC (New Zealand) | 13 Feb 2023 | Non-small cell lung cancer, locally advanced or metastatic, high (>50%) PD-L1 expression, 1st line monotherapy | PTAC advice: No Formal Recommendation · decision reached | source |
115 further decisions for atezolizumab, across 13 agencies, are not shown here. They include the most recent record on file, 29 Jul 2026 from DMC (Denmark); its outcome is in the subscriber dataset. They link to 92 further source documents.
Related molecules
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
- everolimus — same ATC class L01X — Antineoplastics
Coverage: 120 decisions for atezolizumab from 14 agencies, 2017 to 2026. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.